Our Mission:
Accelerating the prevention and cure of myeloma and improving
the quality of life for patients and families
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
This week’s blog covers frequently asked questions (FAQs) on the FDA accelerated approval of ZENBEXUS™ (iberdomide), in combination with Darzalex Faspro® (daratumumab and hyaluronidase-fihj) and dexamethasone as treatment for adults with relapsed/refractory myeloma (RRMM). Iberdomide is the first cereblon-modulating protein degrader (CELMoD) for multiple myeloma that received accelerated approval from the FDA.
An accelerated approval is a U.S. FDA regulatory pathway that can allow approval of a drug for a serious condition based on evidence involving a surrogate endpoint that is considered reasonably likely to predict clinical benefit. READ THE BLOG.
Today, the International Myeloma Foundation (IMF) announced the launch of the US Myeloma Network (USMN) — a first-of-its-kind national clinical research network designed to accelerate the prevention and cure of multiple myeloma by advancing scientific discovery, expanding access to clinical trials, and ensuring more patients benefit from breakthrough therapies. Johnson & Johnson joins this initiative as the network’s first industry collaborator. The USMN will focus on clinical trials with the potential to change clinical practice across care settings, accelerating the delivery of innovative therapies and new treatment approaches to patients. Read the full press release to learn more. READ THE PRESS RELEASE.
In case you missed it, a replay of the following webinar is now available: "Living Well with Myeloma: Beyond Survival: Embracing Sexuality Through the Cancer Journey." Monika Brown, MSN, WHNP-BC, a Women’s Health Nurse Practitioner with 14 years of specialized experience in gynecologic oncology, explores the many ways cancer and its treatment can affect sexual health and intimacy. WATCH NOW.
The IMF offers Myeloma Community Workshops (MCWs), which are shorter, yet still robust, programs in cities across the U.S. Learn more about MCWs in San Diego, CA; and Phoenix, CA; or about an upcoming Virtual MCW. LEARN MORE HERE.
When you volunteer to organize a community fundraiser for the IMF, you receive support and guidance from the IMF's Development Team. Whether it's a 5K Walk/Run, a bake sale, or a simple letter-writing campaign, we're here to help you.
